Drugmakers Ask to Join Hospital Lawsuit, Seeking to Defend Federal 340B Rebate Pilot

Four drug industry parties are asking a federal court for permission to help defend a Trump administration pilot that hospitals are trying to block. On Oct. 14, AbbVie, Bristol-Myers Squibb and Boehringer Ingelheim filed a motion to intervene in the American Hospital Association's lawsuit against the Department of Health and Human Services. PhRMA, the drug lobby, filed its own motion separately. [1]

The pilot would change how drugs are priced under the 340B program, swapping discounts given at the time of purchase for rebates paid afterward. Hospitals challenged it earlier in October. The drugmakers say HHS cannot be relied on to represent their interests or to show the financial effect if the pilot is cancelled, and they want to speak for themselves in court. [1] No court ruling on the new motions was reported.

Whose Side the Drugmakers Are On

The filings back the pilot rather than attack it. The companies say rebates would help limit abuse of the program, and they are worried about money they could lose if a court stops the pilot before it starts. [1]

Boehringer Ingelheim said in a court filing that providers' use of duplicate discounts across 340B and other federal programs costs it an average of $3 million a week. It expects larger losses when the maximum fair price set by the Centers for Medicare and Medicaid Services takes effect next year for two of its drugs, Ofev and Tradjenta. Bristol-Myers Squibb said it has already lost $40 million to duplicate discounts, and AbbVie said it expects to lose tens of millions, according to the filing. [1] By Plocamium's arithmetic, Boehringer's weekly figure comes to about $156 million over a 52-week year.

PhRMA, which the report describes as the largest pharmaceutical trade association in the U.S., argued that it would add an industry-wide view that HHS alone cannot provide. It also anticipated that the plaintiffs would say intervention would complicate the case, and called that argument one that should carry no weight. [1]

A Second Round

This is the second attempt at the pilot, the second hospital lawsuit and the second push by drugmakers to get involved. In the first round last year, hospitals won and HHS dropped the pilot. In July, the administration said it would try again, and hospital groups sued again in October, saying a switch to rebates would threaten the finances of safety-net providers in the program. [1]

The earlier request failed. A judge denied the motions from PhRMA and manufacturers, finding they had no "tangible basis" for doubting that the government could represent their interests. PhRMA now says that outcome proved its point, because HHS agreed to the vacatur and, in PhRMA's account, played down the drugmakers' financial harm. To succeed this time, the companies must show a plausible risk that HHS will not adequately represent them. [1]

What 340B Is

Congress created 340B in 1992. It lets providers that serve many low-income and uninsured patients buy popular drugs at discounts of 25% to 50% off list price. Providers describe it as a lifeline for safety-net institutions on tight budgets. Drugmakers say some providers abuse it, including through prohibited duplicate discounts, and point to spending growth: providers bought $100 billion of 340B drugs last year, up 23% from the prior year and more than double the 2021 level. [1] By Plocamium's arithmetic, a 23% rise to $100 billion implies roughly $81 billion in the year before.

The Plocamium View

The facts support a narrower reading than a broad industry offensive. The pilot is the administration's policy, hospitals are the plaintiffs, and drugmakers are asking to stand beside the government. The sides are clear, but the outcome is not, because no ruling on the drugmakers' request was reported.

The first point to watch is the ruling on the motions. The earlier court turned the same request away on the ground that HHS could represent the drugmakers, and the new filings are built to answer that finding. If a judge lets the companies in, the pilot will have defenders who can argue the financial case themselves. If not, the outcome rests on HHS alone.

The second is the pilot's fate. The first version ended with a hospital win and a government retreat. Whether the second version survives, and in what form, determines whether rebates replace upfront discounts at all.

The third is exposure for hospital-facing businesses. Providers argue that the rebate switch threatens safety-net finances, while manufacturers argue that the current system leaks money through duplicate discounts. Investors with exposure to 340B hospitals or to drug manufacturers should read the court docket before reading the headlines. The company loss figures come from the drugmakers' own filing, and the report does not say a court has tested them.

Correction, Nov. 5, 2026: An earlier version of this article reversed the roles in this case. It described the drugmakers' filings as a legal offensive against the 340B pilot and as an effort to limit government-mandated discounting. In fact the American Hospital Association sued HHS to stop the pilot, and AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim and PhRMA filed motions to join the case to defend it, saying rebates would curb duplicate discounts. The earlier version also said the drugmakers were intervening; they have only filed motions, with no ruling reported, and a judge denied the same request in the earlier lawsuit. Its private equity analysis rested on the reversed premise and on claims that do not appear in the source report, including a figure for federal healthcare spending and a personnel move at a buyout firm. Those passages have been removed.